Purpose of the development: To overcome the drug resistance of anticancer drugs.

Recommended application field: The medicine. Oncological clinics and patients with malignant neoplasms in the treatment of which platinum preparations are used.

Advantages over analogues: There are no direct analogues of this development, the comparison can be made only with platinum preparations. However, Feroplat has significant pharmacological advantages over the free form of cisplatin. It is capable of selective accumulation in the tumor focus, and therefore exhibits less systemic toxicity, the use of Feroplat allows first of all to reduce the nephrotoxicity of cisplatin. Unlike standard cisplatin chemotherapy, Feroplat is more active against cisplatin-resistant tumors. The unique technological properties, high innovative potential of a modern medicine, combines successful technical solutions and pharmaceutical capabilities of the free drug cisplatin, confirmed in an experiment on animals - indicators of nanocomposite pharmacokinetics, effective inhibition of tumor growth and reduction in the size of the tumor node. The obtained results and the conducted preclinical trials of a nanocomposite are a weighty basis for realizing the prospect of clinical studies and the further application of Feroplat in clinical practice. The development solves a very urgent problem of oncology - overcoming the drug resistance of anticancer drugs.

The development stage readiness: Ready for application

Description of the development:
()
An antitumor ferromagnetic nanocomposite for overcoming drug resistance is capable of selective accumulation in a tumor focus and demonstrates sufficient antitumor activity for tumors with a drug resistance phenotype and has the same level of safety to healthy body tissues as official cytostatic. The involvement of modern nanotechnology has allowed the creation of a Feroplat nanocomposite, a new dosage form based on conjugated ferromagnetics and cisplatin. The use of "Feroplat" and a static magnetic field leads to a selective increase in the concentration of cytostatics in the tumor

Information about newness of the development:
there are Ukrainian patents -- 1 items

ноу-хау--
1 шт.

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level
Creation of joint enterprise

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua